{
  "id": [
    "PMC7518729"
  ],
  "source": [
    "PMC"
  ],
  "pmcid": [
    "PMC7518729"
  ],
  "fullTextIdList": [
    {
      "fullTextId": [
        "PMC7518729"
      ]
    }
  ],
  "title": [
    "Drug Repositioning for COVID-19 Reposicionamiento de medicamentos para COVID-19"
  ],
  "authorString": [
    "Benavides-Cordoba V."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Benavides-Cordoba V"
          ],
          "firstName": [
            "Vicente"
          ],
          "lastName": [
            "Benavides-Cordoba"
          ],
          "initials": [
            "V"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "1  Universidad del Valle, Facultad de Salud, Escuela de Ciencias Básicas. Cali, Colombia"
              ]
            }
          ]
        }
      ]
    }
  ],
  "dataLinksTagsList": [
    {
      "dataLinkstag": [
        "supporting_data"
      ]
    }
  ],
  "journalInfo": [
    {
      "issue": [
        "2"
      ],
      "volume": [
        "51"
      ],
      "journalIssueId": [
        "3029465"
      ],
      "dateOfPublication": [
        " "
      ],
      "monthOfPublication": [
        "0"
      ],
      "yearOfPublication": [
        "0"
      ],
      "journal": [
        {
          "title": [
            "Colombia medica (Cali, Colombia)"
          ],
          "ISOAbbreviation": [
            "Colomb. Med."
          ],
          "medlineAbbreviation": [
            "Colomb Med (Cali)"
          ],
          "NLMid": [
            "9212578"
          ],
          "ISSN": [
            "0120-8322"
          ],
          "ESSN": [
            "1657-9534"
          ]
        }
      ]
    }
  ],
  "abstractText": [
    "Abstract Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. With the advance of COVID-19 and the pandemic declaration; It has become the closest alternative to reduce the advance of the virus. Antimalarial, antiviral drugs, antibiotics, glucocorticoids, monoclonal antibodies, among others, are being studied; their findings, although preliminary, could establish a starting point in the search for a solution. In this review, we present a selection of drugs, of different classes and with potential activity against COVID-19, whose trials are ongoing; and as proofs of concept, double blind, add-on event-driven, would allow proposing research that generates results in less time and preserving quality criteria for drug development and approval by regulatory agencies."
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Undetermined"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "review-article",
        "Review",
        "Journal Article"
      ]
    }
  ],
  "keywordList": [
    {
      "keyword": [
        "Drug",
        "Pandemics",
        "Drug Repositioning",
        "Medicamentos",
        "Pandemia",
        "Alternativas Terapéuticas",
        "Therapeutic Alternatives",
        "Covid-19",
        "Reposicionamiento De Medicamentos"
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Free"
          ],
          "availabilityCode": [
            "F"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "PubMedCentral"
          ],
          "url": [
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518729/?tool=EBI"
          ]
        },
        {
          "availability": [
            "Free"
          ],
          "availabilityCode": [
            "F"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "PubMedCentral"
          ],
          "url": [
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518729/pdf/?tool=EBI"
          ]
        },
        {
          "availability": [
            "Free"
          ],
          "availabilityCode": [
            "F"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7518729"
          ]
        },
        {
          "availability": [
            "Free"
          ],
          "availabilityCode": [
            "F"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7518729?pdf=render"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "Y"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "N"
  ],
  "citedByCount": [
    "0"
  ],
  "hasData": [
    "Y"
  ],
  "hasReferences": [
    "N"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "N"
  ],
  "license": [
    "cc by-nc-nd"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "Y"
  ],
  "tmAccessionTypeList": [
    {
      "accessionType": [
        "doi"
      ]
    }
  ],
  "dateOfCreation": [
    "2020-10-06"
  ],
  "firstIndexDate": [
    "2020-10-11"
  ],
  "fullTextReceivedDate": [
    "2020-10-06"
  ],
  "dateOfRevision": [
    "2020-10-08"
  ],
  "firstPublicationDate": [
    "2020-10-06"
  ]
}